Kevin Kunzmann

Patients with IBD or arthritis were not found to be at a significantly higher risk of serious infection with a biosimilar versus originator of the common drugs.

Research from Spain suggests long-term opioid use to treat fibromyalgia pain significantly raises the risk of depression, anxiety and sleep disorders in patients.

Roy Morello, MD, discusses his team's research into the causes of poor pulmonary function among patients with osteogenesis imperfecta—better known as "brittle bone disease."

Uric acid levels, commonly used to indicate gout, are closely associated with bipolar-affected mania.

Amanda Mixon, PA-C, discusses how rheumatic diseases may first present in skin, ocular or gastric symptoms.

Amanda Mixon, PA-C, discusses the need to better bridge the rheumatology and dermatology care teams due to overlapping diseases.

Benjamin J. Smith, DMSc, PA-C, discusses the importance of defining comorbidities in diagnosing PsA, as well as prescribing biologics.

Data presented at NKF Spring Clinical Meeting suggest events including myocardial infarction and stroke are more prevalent among patients with lupus in North America.

A new review considers how SGLT2 inhibitors like dapagliflozin and empagliflozin have been shown to clinically improve gout while reducing its cardiometabolic and renal comorbidities.

Despite being a rare occurrence, the infection was linked to deaths in 1 in 5 observed patients.

A new study suggests patients with either rheumatoid arthritis or osteoarthritis may be at a higher genetic susceptibility to develop COPD.

A comparison of the urate-lowering therapies shows discrepancies in short- and long-term use outcomes.

New 5 year data from the phase 3 SELECT-COMPARE trial suggest a patient with RA not responding to adalimumab or upadacitinib may fare better switching to the other.

The submission could grant guselkumab its third indication, after being approved by the FDA for psoriasis and psoriatic arthritis.

Patients with both psoriasis and psoriatic arthritis may be more likely to be tired based on symptom severity.

A retrospective cohort analysis suggests the monoclonal antibody may help patients with SLE reduce their reliance on oral corticosteroids over 1 year after initiating treatment.

We kick off our annual recap series with some reflections from our expert advisory board, on topics ranging from AI and cell therapies, to semaglutide and RSV vaccines.

The indication for the intravenous formulation is for adults with RA, as well as adults and children with either active PJIA or systemic JIA.

A network meta-analysis lends "compelling" support to the practice of switching patients with RA from biologics to less costly biosimilars at 6 months.

A nationwide cohort study shows individuals with a history of infection are at a nearly 50% greater likelihood of dementia development in older age.

The long-term extension SENSCIS-ON trial shows patients receiving nintedanib over 3 years were not at significantly greater risk of serious adverse events or outcomes.

CCR East 2023 data show ixekizumab bettered adalimumab on measures of joint pain and quality of life in patients with PsA and concomitant nail plus DIP involvement.

Post-hoc analysis from DISCOVER-2 show patients who achieve a clinical response by week 8 generally go on to see quality-of-life improvements past 1 year.

An analysis of 11 late-stage clinical trials shows guselkumab provides a consistent and comparable safety profile to placebo in treated patients.

Therapies including biologics and corticosteroids were more frequently used among patients with rheumatoid arthritis and lupus who developed severe COVID-19.

New data from CCR East show Black and Hispanic patients with PsA are significantly more likely to report worse health-related quality of life than White patients.

Patients with psoriatic arthritis and/or psoriasis reported improved BMI and HbA1C after 6 months of apremilast—with pronounced benefit among patients with obesity.

A comparison of monotherapy biologic or targeted synthetic DMARDs initiated in naive patients show each are beneficial for rheumatoid arthritis.

Data from the UPLIFT study show patients with psoriatic arthritis and their physicians see eye-to-eye on most subjects—except for treatment goals.